ORMP
Oramed Pharmaceuticals Inc
$2.61
Earnings Summary
Revenue | $0.67Mn |
Net Profits | $2.48Mn |
Net Profit Margins | 367.66% |
Highlights
Oramed Pharmaceuticals Inc’s revenue jumped 0% since last year same period to $0.67Mn in the Q2 2023. On a quarterly growth basis, Oramed Pharmaceuticals Inc has generated -75.06% fall in its revenue since last 3-months.
Oramed Pharmaceuticals Inc’s net profit jumped 123.53% since last year same period to $2.48Mn in the Q2 2023. On a quarterly growth basis, Oramed Pharmaceuticals Inc has generated -93.22% fall in its net profits since last 3-months.
Oramed Pharmaceuticals Inc’s net profit margin jumped 123.53% since last year same period to 367.66% in the Q2 2023. On a quarterly growth basis, Oramed Pharmaceuticals Inc has generated -72.82% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Oramed Pharmaceuticals Inc post its latest quarter earnings
EPS Estimate Current Quarter | -0.1 |
EPS Estimate Current Year | -0.1 |
Highlights
Oramed Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.1 - a 46.67% jump from last quarter’s estimates.
Oramed Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.1.
Key Ratios
Key ratios of the Oramed Pharmaceuticals Inc post its Q3 2023 earnings
Earning Per Share (EPS) | 0 |
Highlights
Oramed Pharmaceuticals Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2023. This indicates that the Oramed Pharmaceuticals Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2023-08-10 | -0.19 | 0 | 100% |
2023-11-10 | -0.1 | 0 | 100% |
2023-03-06 | -0.24 | 0 | 100% |
₹0 US Stocks a/c Opening Fee